Research programme: anticancer therapeutics - PEEL Therapeutics
Alternative Names: EP53 Lipid nanoparticlesLatest Information Update: 09 Mar 2021
At a glance
- Originator PEEL Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Tumor suppressor protein p53 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer